Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
17 Novembro 2023 - 10:00AM
Rezolute, Inc. (Nasdaq: RZLT), a
clinical-stage biopharmaceutical company committed to
developing novel, transformative therapies for serious
metabolic and rare diseases, today announced that the management
team will participate in BTIG’s 3rd Annual Ophthalmology Day,
taking place virtually on November 27th.
The Rezolute team is scheduled to participate in
a question and answer session on November 27th at 11:30 am PT /
2:30 pm ET, including a discussion of RZ402, its oral plasma
kallikrein inhibitor for diabetic macular edema. The Company will
also hold investor meetings over the course of the conference
day.
About Rezolute, Inc.Rezolute strives to develop
transformative therapies for devastating rare and chronic metabolic
diseases. Its novel therapies hold the potential to significantly
improve outcomes as well as reduce the treatment burden for
patients, treating physicians, and the healthcare system. Rezolute
is steadfast in its mission to create profound, positive, and
lasting impacts on patients’ lives. Patient, clinician, and
advocate voices are integrated in the Company’s drug development
process. Rezolute places an emphasis on understanding the patient’s
lived experiences, enabling the Company to boldly address a range
of severe conditions. For more information,
visit www.rezolutebio.com.
Forward-Looking StatementsThis release, like
many written and oral communications presented by Rezolute and our
authorized officers, may contain certain forward-looking statements
regarding our prospective performance and strategies within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act of 1934, as amended. We intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 and are including this
statement for purposes of said safe harbor provisions.
Forward-looking statements, which are based on certain assumptions
and describe future plans, strategies, and expectations of
Rezolute, are generally identified by use of words such as
"anticipate," "believe," "estimate," "expect," "intend," "plan,"
"project," "seek," "strive," "try," or future or conditional verbs
such as "could," "may," "should," "will," "would," or similar
expressions.
These forward-looking statements include, but are
not limited to and statements regarding PRIME designation and the
designation’s meaning on the ability of RZ358 to become an
effective treatment to congenital HI, the effectiveness or future
effectiveness of RZ358 for the treatment of congenital HI, and
statements regarding clinical trial timelines for RZ358. Our
ability to predict results or the actual effects of our plans or
strategies is inherently uncertain. Accordingly, actual results may
differ materially from anticipated results. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release. Except as required
by applicable law or regulation, Rezolute undertakes no obligation
to update these forward-looking statements to reflect events or
circumstances that occur after the date on which such statements
were made. Important factors that may cause such a difference
include any other factors discussed in our filings with the SEC,
including the Risk Factors contained in the Rezolute’s Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q, which are
available at the SEC’s website at www.sec.gov. You are urged to
consider these factors carefully in evaluating the forward-looking
statements in this release and are cautioned not to place undue
reliance on such forward-looking statements, which are qualified in
their entirety by this cautionary statement.
Investors:Stephanie CarringtonICR
WestwickeRezoluteIR@westwicke.com(646)277-1282
Media:media-relations@rezolutebio.com
Rezolute (NASDAQ:RZLT)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Rezolute (NASDAQ:RZLT)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024